Moleculin Biotech (MBRX) Short Interest Ratio & Short Volume $1.06 +0.04 (+3.92%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Moleculin Biotech Short Interest DataMoleculin Biotech (MBRX) has a short interest of 465,200 shares, representing 3.32% of the float (the number of shares available for trading by the public). This marks a -18.69% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.1, indicating that it would take 0.1 days of the average trading volume of 1.44 million shares to cover all short positions.Current Short Interest465,200 sharesPrevious Short Interest572,100 sharesChange Vs. Previous Month-18.69%Dollar Volume Sold Short$394,954.80Short Interest Ratio0.1 Days to CoverLast Record DateApril 15, 2025Outstanding Shares14,000,000 sharesFloat Size14,010,000 sharesShort Percent of Float3.32%Today's Trading Volume192,711 sharesAverage Trading Volume1,443,708 sharesToday's Volume Vs. Average13% Short Selling Moleculin Biotech? Sign up to receive the latest short interest report for Moleculin Biotech and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartMBRX Short Interest Over TimeMBRX Days to Cover Over TimeMBRX Percentage of Float Shorted Over Time Moleculin Biotech Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/2025465,200 shares $394,954.80 -18.7%3.3%0.1 $0.85 3/31/2025572,100 shares $554,937.00 +23.4%4.1%0.1 $0.97 3/15/2025463,600 shares $523,868.00 -57.1%3.3%0.1 $1.13 2/28/20251,080,000 shares $1.39 million -50.9%8.4%0.2 $1.29 2/15/20252,200,000 shares $4.80 million +1,169.5%54.6%0.4 $2.18 1/31/2025173,300 shares $261,683.00 +2.0%5.3%1.3 $1.51 1/15/2025169,900 shares $307,519.00 +106.9%5.5%3.2 $1.81 12/31/202482,100 shares $139,570.00 +139.4%2.7%1.6 $1.70 12/15/202434,300 shares $79,576.00 +65.7%1.1%0.7 $2.32 11/30/202420,700 shares $57,339.00 -61.7%0.7%0.5 $2.77 Get the Latest News and Ratings for MBRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter. 11/15/202454,100 shares $146,611.00 -55.8%1.9%1.3 $2.71 10/31/2024122,400 shares $318,240.00 -28.6%4.5%3.8 $2.60 10/15/2024171,500 shares $399,595.00 +0.4%6.3%4.2 $2.33 9/30/2024170,900 shares $485,356.00 +36.5%6.2%4.3 $2.84 9/15/2024125,200 shares $304,236.00 +17.0%4.6%3.4 $2.43 8/31/2024107,000 shares $272,850.00 +108.6%3.9%3.3 $2.55 8/15/202451,300 shares $114,399.00 +83.9%1.9%1.6 $2.23 7/31/202427,900 shares $87,885.00 +30.4%1.1%1 $3.15 7/15/202421,400 shares $90,308.00 -28.7%1.0%1 $4.22 6/30/202430,000 shares $105,600.00 +31.0%1.4%1.4 $3.52 6/15/202422,900 shares $94,806.00 +8.5%1.0%0.6 $4.14 5/31/202421,100 shares $100,647.00 -38.3%1.0%0.5 $4.77 5/15/202434,200 shares $168,264.00 +10.0%1.5%0.9 $4.92 4/30/202431,100 shares $156,122.00 +16.5%1.5%0.8 $5.02 4/15/202426,700 shares $119,082.00 -40.7%1.2%0.8 $4.46 3/31/202445,000 shares $265,950.00 +2,042.9%2.1%1.4 $5.91 3/15/20242,100 shares $15,576.75 -98.4%0.1%0.1 $7.42 2/29/2024134,400 shares $84,537.60 -2.4%N/A0.8 $0.63 2/15/2024137,700 shares $68,850.00 -37.4%N/A0.9 $0.50 1/31/2024220,000 shares $110,880.00 -8.5%N/A1.2 $0.50 1/15/2024240,300 shares $170,613.00 -23.8%N/A1.3 $0.71 12/31/2023315,300 shares $270,653.52 -7.5%N/A1.6 $0.86 12/15/2023340,800 shares $197,664.00 +35.3%N/A2.1 $0.58 11/30/2023251,900 shares $150,812.53 -15.2%N/A1.7 $0.60 11/15/2023296,900 shares $169,233.00 +59.7%N/A1.9 $0.57 10/31/2023185,900 shares $90,012.78 +131.8%N/A1.5 $0.48 10/15/202380,200 shares $36,090.00 -55.3%N/A0.7 $0.45 9/30/2023179,300 shares $76,650.75 +260.0%N/A1.2 $0.43 9/15/202349,800 shares $19,770.60 +30.7%N/A0.3 $0.40 8/31/202338,100 shares $21,336.00 -75.4%N/A0.2 $0.56The Man I Turn to In Times Like This (Ad)A storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.Market chaos? Hear Tilson’s take now 8/15/2023155,100 shares $94,455.90 +15.6%N/A1 $0.61 7/31/2023134,200 shares $84,975.44 +42.6%N/A0.7 $0.63 7/15/202394,100 shares $59,283.00 -20.8%N/A0.5 $0.63 6/30/2023118,800 shares $68,761.44 +611.4%N/A0.4 $0.58 6/15/202316,700 shares $9,853.00 +108.8%N/A0.1 $0.59 5/31/20238,000 shares $5,068.00 -59.4%N/A0 $0.63 5/15/202319,700 shares $12,139.14 +20.9%N/A0.1 $0.62 4/30/202316,300 shares $12,180.99 -30.3%0.1%0.1 $0.75 4/15/202323,400 shares $21,294.00 -14.6%0.1%0.1 $0.91 3/31/202327,400 shares $26,304.00 -26.3%0.1%0.4 $0.96 3/15/202337,200 shares $35,340.00 -13.9%0.1%0.5 $0.95 2/28/202343,200 shares $52,272.00 -30.1%0.2%0.5 $1.21 2/15/202361,800 shares $80,340.00 +56.9%0.2%0.7 $1.30 1/31/202339,400 shares $49,640.06 -49.0%0.1%0.4 $1.26 1/15/202377,200 shares $100,360.00 -34.9%0.3%0.8 $1.30 12/30/2022118,600 shares $125,716.00 +48.3%0.4%1.2 $1.06 12/15/202280,000 shares $110,400.00 -9.7%0.3%0.8 $1.38 11/30/202288,600 shares $127,584.00 +30.3%0.3%0.9 $1.44 11/15/202268,000 shares $64,593.20 +32.0%0.2%0.6 $0.95 10/31/202251,500 shares $51,500.00 -9.8%0.2%0.5 $1.00 10/15/202257,100 shares $57,100.00 -5.3%0.2%0.6 $1.00 9/30/202260,300 shares $63,918.00 -36.4%0.2%0.6 $1.06 9/15/202294,800 shares $134,616.00 -40.0%0.3%1 $1.42 8/31/2022158,100 shares $233,988.00 +59.2%0.6%2 $1.48 8/15/202299,300 shares $178,740.00 +85.6%0.4%2 $1.80 7/31/202253,500 shares $90,415.00 -54.7%0.2%1 $1.69 7/15/2022118,200 shares $195,467.34 +25.5%0.4%2 $1.65 6/30/202294,200 shares $136,590.00 -37.9%0.3%1.4 $1.45 6/15/2022151,600 shares $210,724.00 -39.0%0.5%1.9 $1.39 5/31/2022248,500 shares $372,750.00 +31.0%0.9%2.9 $1.50 5/15/2022189,700 shares $235,228.00 -37.0%0.7%1.9 $1.24 4/30/2022301,000 shares $478,590.00 -28.0%1.1%2.8 $1.59 4/15/2022418,300 shares $836,600.00 +0.6%1.5%3.5 $2.00 3/31/2022415,900 shares $740,302.00 -4.7%1.5%3.4 $1.78 3/15/2022436,400 shares $554,228.00 -9.6%1.6%2.4 $1.27 2/28/2022482,500 shares $670,675.00 +9.2%1.8%2.4 $1.39 2/15/2022441,900 shares $645,174.00 -9.9%1.7%1.8 $1.46 1/31/2022490,200 shares $740,202.00 -7.8%1.8%1.9 $1.51 1/15/2022531,600 shares $909,036.00 +2.0%2.0%1.9 $1.71 12/31/2021521,100 shares $969,246.00 -11.0%1.9%1.8 $1.86 12/15/2021585,400 shares $1.22 million +2.2%2.2%2.3 $2.08 11/30/2021572,600 shares $1.19 million -8.7%2.1%2.4 $2.07 11/15/2021626,800 shares $1.49 million -3.3%2.3%3.2 $2.38 10/29/2021648,000 shares $1.71 million -6.1%2.4%3.5 $2.64 10/15/2021690,400 shares $1.87 million +3.6%2.6%4 $2.71 9/30/2021666,700 shares $2.00 million -6.3%2.5%3.8 $3.00 9/15/2021711,400 shares $2.07 million -5.6%2.7%3.7 $2.91 8/31/2021753,900 shares $2.32 million +5.4%2.8%3.5 $3.08 8/13/2021715,200 shares $2.12 million -7.3%2.7%2.9 $2.97 7/30/2021771,800 shares $2.41 million -18.8%2.9%2.9 $3.12The Man I Turn to In Times Like This (Ad)A storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.Market chaos? Hear Tilson’s take now 7/15/2021949,900 shares $3.25 million -1.0%3.6%3.3 $3.42 6/30/2021959,300 shares $3.52 million +17.8%3.6%1.7 $3.67 6/15/2021814,600 shares $3.08 million -13.8%3.1%0.7 $3.78 5/28/2021944,700 shares $3.50 million -14.9%3.5%0.8 $3.70 5/14/20211,110,000 shares $3.63 million -4.3%4.2%0.9 $3.27 4/30/20211,160,000 shares $4.21 million +26.7%4.4%0.7 $3.63 4/15/2021915,500 shares $3.38 million +78.0%3.4%0.3 $3.69 3/31/2021514,200 shares $2.19 million +70.9%1.9%0.2 $4.25 3/15/2021300,800 shares $1.34 million -50.1%1.1%0.1 $4.44 2/26/2021602,500 shares $2.62 million +44.7%2.6%0.3 $4.35 2/12/2021416,500 shares $2.23 million -84.9%1.8%0.2 $5.36 1/29/20212,760,000 shares $16.06 million +8.2%12.6%1.4 $5.82 1/15/20212,550,000 shares $15.45 million +4.9%N/A1 $6.06 12/31/20202,430,000 shares $12.17 million +4.7%N/A1.2 $5.01 12/15/20202,320,000 shares $10.75 million -0.4%N/A1.6 $4.63 11/30/20202,330,000 shares $10.82 million -7.2%N/A1.7 $4.64 11/15/20202,510,000 shares $11.58 million -3.5%N/A5 $4.61 10/30/20202,600,000 shares $11.23 million -11.3%N/A4.9 $4.32 10/15/20202,930,000 shares $14.29 million -5.5%N/A4.1 $4.88 9/30/20203,100,000 shares $15.12 million +2.0%N/A1 $4.88 9/15/20203,040,000 shares $14.85 million -10.3%N/A1 $4.88 8/31/20203,390,000 shares $17.83 million -7.6%N/A1.1 $5.26 8/14/20203,670,000 shares $21.58 million -5.4%N/A1.1 $5.88 7/31/20203,880,000 shares $26.77 million +19.0%N/A1.2 $6.90 7/15/20203,260,000 shares $20.93 million -11.7%N/A1 $6.42 6/30/20203,690,000 shares $21.43 million -13.2%N/A0.7 $5.81 6/15/20204,250,000 shares $28.56 million -3.2%N/A0.8 $6.72 5/29/20204,390,000 shares $28.71 million +8.7%N/A0.7 $6.54 5/15/20204,040,000 shares $25.94 million -28.2%N/A0.7 $6.42 MBRX Short Interest - Frequently Asked Questions What is Moleculin Biotech's current short interest? Short interest is the volume of Moleculin Biotech shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 465,200 shares of MBRX short. 3.32% of Moleculin Biotech's shares are currently sold short. Learn More on Moleculin Biotech's current short interest. What is a good short interest percentage for Moleculin Biotech? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 3.32% of Moleculin Biotech's floating shares are currently sold short. Is Moleculin Biotech's short interest increasing or decreasing? Moleculin Biotech saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 465,200 shares, a decrease of 18.7% from the previous total of 572,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Moleculin Biotech's float size? Moleculin Biotech currently has issued a total of 14,000,000 shares. Some of Moleculin Biotech's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Moleculin Biotech currently has a public float of 14,010,000 shares. How does Moleculin Biotech's short interest compare to its competitors? 3.32% of Moleculin Biotech's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Moleculin Biotech: Biodexa Pharmaceuticals Plc (0.80%), Gain Therapeutics, Inc. (1.02%), BeyondSpring Inc. (6.28%), Kronos Bio, Inc. (1.71%), Precision BioSciences, Inc. (21.96%), Immix Biopharma, Inc. (1.16%), OKYO Pharma Limited (0.63%), PepGen Inc. (10.13%), Immuneering Co. (2.97%), Karyopharm Therapeutics Inc. (23.11%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short Moleculin Biotech stock? Short selling MBRX is an investing strategy that aims to generate trading profit from Moleculin Biotech as its price is falling. MBRX shares are trading up $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Moleculin Biotech? A short squeeze for Moleculin Biotech occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of MBRX, which in turn drives the price of the stock up even further. How often is Moleculin Biotech's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MBRX, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies Biodexa Pharmaceuticals Short Squeeze Gain Therapeutics Short Squeeze BeyondSpring Short Squeeze Kronos Bio Short Squeeze Precision BioSciences Short Squeeze Immix Biopharma Short Squeeze OKYO Pharma Short Squeeze PepGen Short Squeeze Immuneering Short Squeeze Karyopharm Therapeutics Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:MBRX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MBRX Stock Free MBRX Stock Alerts